ImaginAb announces a new supply agreement with Invicro to offer clinical doses of CD8 investigational ImmunoPET imaging agent for Immuno-Oncology preclinical and clinical studies

ImaginAb announces a new supply agreement with Invicro to offer clinical doses of CD8 investigational ImmunoPET imaging agent for Immuno-Oncology preclinical and clinical studies

Inglewood, California, May 12^th, 2022 - ImaginAb Inc., a market-leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT), today announced a new agreement with Invicro LLC, a global, industry-leading imaging CRO, and part of REALM IDx, Inc., to supply clinical doses of ImaginAb’s investigational CD8 ImmunoPET agent (zirconium Zr 89 crefmirlimab berdoxam) for use in clinical trials as part of Invicro’s global core lab imaging service. In addition, the agreement allows Invicro to produce zirconium Zr 89 crefmirlimab for its preclinical offerings.

This offering is a response to the growth seen in Immuno-Oncology (I-O) therapies and demand from pharmaceutical and biotech companies for advanced, non-invasive, whole-body imaging biomarkers. ImaginAb’s investigational CD8 ImmunoPET agent provides a number of potential benefits that may help inform early decision making through Phase I-IV clinical trials.

Ian Wilson, CEO of ImaginAb, said: “We are delighted with our agreement with Invicro and the operational benefits we hope it will bring to its customers.

“Arising from discussions with pharma and biotech companies that currently license our technology, we believe this partnership will bring the best of both businesses together, offering the potential benefits of our investigational CD8 ImmunoPET imaging agent in understanding the therapeutic efficacy and treatment outcomes in clinical trials more precisely and at an earlier stage.”

This offering is intended to provide pharma and biotech customers with the opportunity to receive clinical doses of ImaginAb’s investigational CD8 ImmunoPET agent directly from Invicro.

“Invicro’s vision to transform healthcare through advanced imaging technologies aligns with ImaginAb’s investigational CD8 technology and mission. We believe this agreement will offer deeper insights into immune biology and pharmacodynamics that will help advance the development of therapies within the I-O space,” commented Dr. Matthew Silva, CEO of Invicro.